Biocon Biologics to Launch 3 New Cancer Biosimilars

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Biocon Biologics to Launch 3 New Cancer Biosimilars
Overview

Biocon Biologics announced plans Tuesday to launch three significant oncology biosimilars – Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. These cost-effective alternatives aim to broaden access to critical cancer therapies, bolstering Biocon's comprehensive oncology portfolio. The move targets major drug exclusivity losses expected over the next five years.

Biocon Biologics announced Tuesday its strategic move to introduce three new oncology biosimilars, significantly expanding its cancer treatment portfolio. The company plans to unveil Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab at the upcoming 2026 JP Morgan Healthcare Conference in San Francisco.

Pipeline Expansion into High-Value Oncology

These new biosimilar assets target some of the largest oncology biologics scheduled to lose exclusivity in the next five years. This initiative will bolster Biocon Biologics' existing array of 17 oncology medications, including small-molecule therapies and Pertuzumab (Perjeta), which recently underwent submission to the US FDA. The introduction of these complex biologics underscores Biocon's commitment to advancing its research and development capabilities in oncology.

Targeting Blockbuster Market Opportunities

Biocon provided substantial figures on the market potential, noting global sales of Keytruda reached $29.5 billion in 2024, while Opdivo generated $9.3 billion the same year. Combined sales for Herceptin SC and Herceptin HYLECTA stood at $1.72 billion in 2024. By offering cost-effective biosimilar alternatives, Biocon Biologics aims to broaden the accessibility of these critical, life-saving cancer therapies.

Broadening Patient Access and Global Reach

Shreehas Tambe, CEO and Managing Director of Biocon Biologics, emphasized the company's science-led approach. "We are advancing a strong pipeline with 17 oncology assets to meet varied patient needs," Tambe stated. This expansion is poised to enhance Biocon's global presence in oncology, making advanced cancer treatments more affordable and available to a wider patient population.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.